AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39306592 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices (MAD) treatment for OSA.
Number of subjects: 112
Study 39306601 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg twice daily
Number of subjects: 44
Study 39306601 — intervention group
Group type: COMPARATOR
Intervention: Amphetamine-dextroamphetamine 20 mg twice daily
Number of subjects: 44
Study 39306601 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 44
Study 39306665 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg)
Number of subjects: 70
Study 39306665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 39306704 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 144
Study 39306704 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 144
Study 39306798 — intervention group
Group type: COMPARATOR
Intervention: BQT (bismuth quadruple therapy) - 14-day therapy with b.i.d. proton pump inhibitor 20 mg, bismuth 220 mg, tetracycline 400 mg q.i.d, metronidazole 400 mg q.i.d
Number of subjects: 823
Study 39306798 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMn (minocycline-containing therapy) - 14-day therapy with b.i.d. proton pump inhibitor 20 mg, minocycline 50 mg q.i.d, metronidazole 400 mg q.i.d
Number of subjects: 823
Study 39306923 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenously every three weeks
Number of subjects: 18
Study 39307144 — intervention group
Group type: EXPERIMENTAL
Intervention: Rodatristat ethyl 300 mg twice daily
Number of subjects: 108
Study 39307144 — intervention group
Group type: EXPERIMENTAL
Intervention: Rodatristat ethyl 600 mg twice daily
Number of subjects: 108
Study 39307144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 39307154 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 20 mg once a day
Number of subjects: 530
Study 39307154 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 200 mg once a day
Number of subjects: 530
Study 39307154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 39307154 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 530
Study 39307154 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 530
Study 39307186 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 2028
Study 39307186 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2028
Study 39307188 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein and milk carbohydrate (MPMC)
Number of subjects: 413
Study 39307188 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein and vegetable carbohydrate (MPVC)
Number of subjects: 413
Study 39307188 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable protein and milk carbohydrate (VPMC)
Number of subjects: 413
Study 39307188 — intervention group
Group type: COMPARATOR
Intervention: Vegetable-based food (VPVC)
Number of subjects: 413
Study 39307204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 150
Study 39307204 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 150
Study 39307204 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 150
Study 39307204 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 150
Study 39307402 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoZip device (robotic endoscopic suturing)
Number of subjects: 45
Study 39307479 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) defined as an apnea hypopnea index ≥15 events/h.
Number of subjects: 1927
Study 39307479 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in HF patients with preserved ejection fraction.
Number of subjects: 1927
Study 39307479 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) in HF patients with reduced ejection fraction.
Number of subjects: 1927
Study 39307479 — intervention group
Group type: COMPARATOR
Intervention: Patients without heart failure (HF).
Number of subjects: 1927
Study 39307596 — intervention group
Group type: EXPERIMENTAL
Intervention: CP + PRP
Number of subjects: 87
Study 39307596 — intervention group
Group type: COMPARATOR
Intervention: CP
Number of subjects: 87
Study 39307840 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV)
Number of subjects: 215
Study 39308140 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter ductal artery stenting (DAS)
Number of subjects: 236
Study 39308140 — intervention group
Group type: COMPARATOR
Intervention: Surgical systemic-to-pulmonary shunt (SPS)
Number of subjects: 236
Study 39308371 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter shunt implantation
Number of subjects: 508
Study 39308371 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 508
Study 39308652 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal ABI
Number of subjects: 102
Study 39308652 — intervention group
Group type: COMPARATOR
Intervention: Normal ABI
Number of subjects: 102
Study 39308871 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 350
Study 39308871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 39308936 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Intervention (TLI) for both dyadic partners (Case 1)
Number of subjects: 10
Study 39308936 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic Lifestyle Intervention (TLI) for SCI partner only (Case 2)
Number of subjects: 10
Study 39308991 — intervention group
Group type: EXPERIMENTAL
Intervention: 10kHz spinal cord stimulation (SCS)
Number of subjects: 144
Study 39309246 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic lifestyle intervention (TLI) based on the Diabetes Prevention Program (DPP) including circuit resistance training, a Mediterranean-style calorie-restricted diet, and tailored behavioral support.
Number of subjects: 20
Study 39309477 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 39309608 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 53
Study 39309608 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 53
Study 39309608 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 53
Study 39309627 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular Acupressure (AA)
Number of subjects: 114
Study 39309627 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupressure (SA)
Number of subjects: 114
Study 39309703 — intervention group
Group type: EXPERIMENTAL
Intervention: AVATAR-based video immersion with radiation therapy
Number of subjects: 81
Study 39309726 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised remote speech therapy for 8 weeks
Number of subjects: 214
Study 39309726 — intervention group
Group type: COMPARATOR
Intervention: No intervention (waiting list design)
Number of subjects: 214
Study 39309747 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal compressions alone (AC-CPR)
Number of subjects: 11
Study 39309747 — intervention group
Group type: COMPARATOR
Intervention: Standard chest compression CPR (S-CPR)
Number of subjects: 11
Study 39310045 — intervention group
Group type: EXPERIMENTAL
Intervention: CONNECTDROP® Medication Event Monitoring System (MEMS) paired with a smartphone application
Number of subjects: 31
Study 39310667 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP; ∼38% of daily intake as protein)
Number of subjects: 16
Study 39310667 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (NP; ∼15% of daily intake as protein)
Number of subjects: 16
Study 39310666 — intervention group
Group type: EXPERIMENTAL
Intervention: OC+P (50 g prunes daily)
Number of subjects: 90
Study 39310666 — intervention group
Group type: COMPARATOR
Intervention: OC (not consuming prunes)
Number of subjects: 90
Study 39310666 — intervention group
Group type: COMPARATOR
Intervention: Non-OC (control group not using OCs)
Number of subjects: 90
Study 39310769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate concentrates (BMACs) from knee-OA patients; specific dosage and duration not mentioned.
Number of subjects: 0
Study 39311092 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter ductal artery stenting (DAS)
Number of subjects: 236
Study 39311092 — intervention group
Group type: COMPARATOR
Intervention: Surgical systemic-to-pulmonary shunt (SPS)
Number of subjects: 236
Study 39311164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation protocol (RN4HTx)
Number of subjects: 19
Study 39311330 — intervention group
Group type: EXPERIMENTAL
Intervention: AI algorithm for assessing dental panoramic radiographs (DPRs)
Number of subjects: 35
Study 39311502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin sirolimus-eluting Orsiro stent (O-SES)
Number of subjects: 0
Study 39311502 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting Nobori stent (N-BES)
Number of subjects: 0
Study 39311502 — intervention group
Group type: COMPARATOR
Intervention: Patients with diabetes mellitus
Number of subjects: 0
Study 39311597 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (CAB-LA) 600 mg
Number of subjects: 194
Study 39311597 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 194
Study 39311813 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress tolerance (DT)
Number of subjects: 0
Study 39311825 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 152
Study 39311825 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 152
Study 39311941 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus (SV) approach
Number of subjects: 17
Study 39311941 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar (MP) approach
Number of subjects: 17
Study 39312248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain interference
Number of subjects: 514
Study 39312248 — intervention group
Group type: EXPERIMENTAL
Intervention: Tribal identity
Number of subjects: 514
Study 39312248 — intervention group
Group type: COMPARATOR
Intervention: Control for age, gender, food insecurity, anxiety symptoms, and depressive symptoms
Number of subjects: 514
Study 39312291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot-led support combined with counselor-led support
Number of subjects: 0
Study 39312291 — intervention group
Group type: COMPARATOR
Intervention: Control group (brief face-to-face cessation advice and group cessation support led by a chatbot)
Number of subjects: 0
Study 39312301 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM)
Number of subjects: 141
Study 39312301 — intervention group
Group type: COMPARATOR
Intervention: Control (no TTM)
Number of subjects: 141
Study 39312389 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight-bearing
Number of subjects: 4489
Study 39312389 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable ankle support
Number of subjects: 4489
Study 39312389 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy interventions
Number of subjects: 4489
Study 39312625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile massage (TM) for 15 minutes, twice a week for 4 weeks
Number of subjects: 55
Study 39312625 — intervention group
Group type: COMPARATOR
Intervention: Regular care (control group)
Number of subjects: 55
Study 39312715 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK retainers
Number of subjects: 45
Study 39312715 — intervention group
Group type: COMPARATOR
Intervention: DSC retainers
Number of subjects: 45
Study 39312715 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK and DSC retainers
Number of subjects: 45
Study 39312766 — intervention group
Group type: EXPERIMENTAL
Intervention: TOGETHER-YA intervention via website
Number of subjects: 7
Study 39312766 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability testing of TOGETHER-YA website
Number of subjects: 7
Study 39312771 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based PrEP (HB-PrEP) option for 2 of 3 triannual PrEP follow-up visits.
Number of subjects: 458
Study 39312771 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 458
Study 39312920 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus decitabine induction
Number of subjects: 93
Study 39313221 — intervention group
Group type: EXPERIMENTAL
Intervention: soticlestat 300 mg twice daily
Number of subjects: 33
Study 39313221 — intervention group
Group type: EXPERIMENTAL
Intervention: soticlestat N-oxide metabolite plasma concentrations
Number of subjects: 33
Study 39313221 — intervention group
Group type: COMPARATOR
Intervention: soticlestat in Part 2
Number of subjects: 33
Study 39313221 — intervention group
Group type: EXPERIMENTAL
Intervention: soticlestat at therapeutic doses
Number of subjects: 33
Study 39313221 — intervention group
Group type: EXPERIMENTAL
Intervention: soticlestat in scenarios of high clinical exposures
Number of subjects: 33
Study 39313222 — intervention group
Group type: EXPERIMENTAL
Intervention: Registered nurse understaffing
Number of subjects: 213910
Study 39313222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse assistant understaffing
Number of subjects: 213910
Study 39313281 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective and emergency paediatric surgery
Number of subjects: 0
Study 39313282 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive surgery
Number of subjects: 80
Study 39313286 — intervention group
Group type: EXPERIMENTAL
Intervention: Acustimulation combined with pharmacological prophylaxis
Number of subjects: 302
Study 39313286 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation combined with pharmacological prophylaxis
Number of subjects: 302
Study 39313288 — intervention group
Group type: COMPARATOR
Intervention: Standard dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine
Number of subjects: 10
Study 39313288 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine
Number of subjects: 10
Study 39313302 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg Q4W
Number of subjects: 1112
Study 39313302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1112
Study 39313307 — intervention group
Group type: EXPERIMENTAL
Intervention: TraditionCART
Number of subjects: 22
Study 39313307 — intervention group
Group type: EXPERIMENTAL
Intervention: InstanCART
Number of subjects: 22
Study 39313594 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib (Enco) + Cetuximab (Cetux) ± Binimetinib (Bini)
Number of subjects: 0
Study 39313594 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (Cetux) + chemotherapy
Number of subjects: 0
Study 39313860 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic capsular tension ring (CTR) implantation
Number of subjects: 110
Study 39313860 — intervention group
Group type: COMPARATOR
Intervention: Non-CTR group
Number of subjects: 110
Study 39313857 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine (CoronaVac®) co-administered with inactivated enterovirus type 71 vaccine (Inlive®)
Number of subjects: 0
Study 39313857 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study 39314107 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic agents (e.g., botulinum toxin type A, injectable fillers, chemical peels)
Number of subjects: 0
Study 39314107 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 39314125 — intervention group
Group type: EXPERIMENTAL
Intervention: HepB-BD in addition to HepB3 (group U4)
Number of subjects: 281
Study 39314125 — intervention group
Group type: COMPARATOR
Intervention: Standard HepB3 vaccine series (group U3)
Number of subjects: 281
Study 39314125 — intervention group
Group type: EXPERIMENTAL
Intervention: HepB-BD and HepB3 (group E4)
Number of subjects: 281
Study 39314260 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilucoplan
Number of subjects: 0
Study 39314260 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard of care)
Number of subjects: 0
Study 39314261 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin treatment
Number of subjects: 57
Study 39314676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) proteomics
Number of subjects: 0
Study 39314676 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum proteomics
Number of subjects: 0
Study 39314676 — intervention group
Group type: EXPERIMENTAL
Intervention: AHC clustering
Number of subjects: 0
Study 39314676 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal serum analysis
Number of subjects: 0
Study 39314676 — intervention group
Group type: EXPERIMENTAL
Intervention: CM-to-EM reversion analysis
Number of subjects: 0
Study 39314676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway analysis
Number of subjects: 0
Study 39314770 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure (BP) categories
Number of subjects: 1213
Study 39314770 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Pressure (BP) categories (specifically hypertension grade 1)
Number of subjects: 1213
Study 39315230 — intervention group
Group type: COMPARATOR
Intervention: Monofocal theta tACS
Number of subjects: 0
Study 39315230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal in-phase theta tACS
Number of subjects: 0
Study 39315230 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-frequency stimulations
Number of subjects: 0
Study 39315253 — intervention group
Group type: COMPARATOR
Intervention: GlobalConsent educational program
Number of subjects: 0
Study 39315334 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 19615
Study 39315334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 19615
Study 39315334 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated control
Number of subjects: 19615
Study 39315465 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative Multipoint Impedance-Controlled Radiofrequency Ablation of the Posterior Nasal Nerve
Number of subjects: 0
Study 39315465 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39315857 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Number of subjects: 372
Study 39315857 — intervention group
Group type: COMPARATOR
Intervention: Vorinostat
Number of subjects: 372
Study 39315857 — intervention group
Group type: EXPERIMENTAL
Intervention: Skindex-29
Number of subjects: 372
Study 39315857 — intervention group
Group type: EXPERIMENTAL
Intervention: ItchyQol
Number of subjects: 372
Study 39315857 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 372
Study 39315864 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF/MEK inhibitors (encorafenib and binimetinib) followed by immune checkpoint inhibitors (ipilimumab and nivolumab)
Number of subjects: 206
Study 39315864 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ipilimumab and nivolumab) followed by BRAF/MEK inhibitors (encorafenib and binimetinib)
Number of subjects: 206
Study 39315864 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAF/MEK inhibitors (encorafenib and binimetinib) for 8 weeks followed by immune checkpoint inhibitors (ipilimumab and nivolumab) and retreatment with BRAF/MEK inhibitors
Number of subjects: 206
Study 39315892 — intervention group
Group type: EXPERIMENTAL
Intervention: RISA-PE stage A (right ventricular dysfunction and troponin elevation)
Number of subjects: 334
Study 39315892 — intervention group
Group type: EXPERIMENTAL
Intervention: RISA-PE stage B (A + serum lactate >2 mmol/L OR shock index ≥1)
Number of subjects: 334
Study 39315892 — intervention group
Group type: EXPERIMENTAL
Intervention: RISA-PE stage C (persistent hypotension)
Number of subjects: 334
Study 39315892 — intervention group
Group type: EXPERIMENTAL
Intervention: RISA-PE stage D (obstructive shock)
Number of subjects: 334
Study 39315892 — intervention group
Group type: EXPERIMENTAL
Intervention: RISA-PE stage E (cardiac arrest)
Number of subjects: 334
Study 39315892 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC classification for IHR-PE
Number of subjects: 334
Study 39315892 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC classification for HR-PE
Number of subjects: 334
Study 39315892 — intervention group
Group type: EXPERIMENTAL
Intervention: RISA-PE classification
Number of subjects: 334
Study 39315986 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions (MBIs) assessed using the Five Factor Mindfulness Questionnaire (FFMQ)
Number of subjects: 0
Study 39315986 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39316026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling plus omega-3 supplementation
Number of subjects: 50
Study 39316026 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 50
Study 39316126 — intervention group
Group type: EXPERIMENTAL
Intervention: High training status
Number of subjects: 971
Study 39316126 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium training status
Number of subjects: 971
Study 39316126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low training status
Number of subjects: 971
Study 39316164 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin Symptom Assessment (SSA) questionnaire
Number of subjects: 414
Study 39316164 — intervention group
Group type: COMPARATOR
Intervention: Radiation-Induced Skin Reaction Assessment Scale (RISRAS) questionnaire
Number of subjects: 414
Study 39316242 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up Online (FCU-O)
Number of subjects: 161
Study 39316242 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 161
Study 39316284 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC 200 mg BID
Number of subjects: 551
Study 39316284 — intervention group
Group type: COMPARATOR
Intervention: tramadol 50 mg QID
Number of subjects: 551